NCT00738049View on ClinicalTrials.gov

Darusentan Effect on PET Uptake Heterogeneity

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Coronary Artery DiseaseEndothelial Dysfunction
Interventions
DRUG

darusentan 100 mg

All subjects will receive oral darusentan 100 mg for a total of 2 weeks and placebo for 2 weeks.

Trial Locations (1)

77030

Weatherhead PET Center for Preventing and Reversing Atherosclerosis, UT Medical School, Memorial Hermann Hospital, Houston

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

K.Lance Gould

OTHER